Short answer
Janux Therapeutics, Inc. (JANX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $9M (down 7.1% year over year) with net income of −$22M.
Q3 2026 key financials · XBRL
- Revenue
- $9M
- −7.1% YoY · −9.5% QoQ
- Net income
- −$22M
- +11.3% YoY · +1.8% QoQ
- Operating margin
- -336.5%
- EPS (diluted)
- −$0.34
- +12.8% YoY · +2.9% QoQ
Source: XBRL data from the Janux Therapeutics, Inc. (JANX) Q3 2026 10-Q on SEC EDGAR. USD.
Janux Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $9.3M, down $0.7M YoY, BMS revenue offsetting lower Merck revenue
- Net loss $21.6M vs $24.3M YoY, operating loss $31.3M vs $35.3M
- JANX007 highest R&D spend at $6.7M, up $0.5M; JANX013 lowest at $1.0M, down $2.6M
- Cash, restricted cash and short-term investments $946.5M; operating cash use $25.0M vs $53.7M YoY
- Existing liquidity expected to fund operations and capital expenditures through at least the next 12 months; clinical spending headwind
Risk Factors
- Clinical discontinuation of JANX008 in April 2026 after Phase 1a activity proved insufficient versus other pipeline programs
- Regulatory risk: U.S. FDA staffing cuts may delay IND reviews, guidance and future approvals
- Manufacturing concentration: BDS for each product candidate expected to rely on single-source suppliers
- Liquidity risk: $945.7 million in cash, equivalents and short-term investments funds operations for at least 12 months
- Competitive risk: larger biopharmaceutical companies may develop safer, more effective or cheaper immunotherapies faster
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Janux Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.